A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation
Theranostics · 2026
DOI: 10.7150/thno.123726 ↗At a glance
Journal article in Theranostics, 2026. Written by Zhenzhen Yin and 14 co-authors. Institution: Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. Major MEDLINE topics: Immune Checkpoint Inhibitors, Cochlea, Neurilemmoma, Membrane Proteins. The full text is freely available in PubMed Central. Funded by: NIDCD NIH HHS, NINDS NIH HHS.
Abstract (original language)
Rationale
NF2-related schwannomatosis (NF2-SWN) is a progressive neurological disorder with a hallmark of bilateral vestibular schwannomas (VSs), leading to irreversible hearing loss and reduced quality of life. To date, the FDA has not approved any pharmacological therapies for treating VS or hearing loss. While radiotherapy (RT) is the standard treatment for growing VSs, it often exacerbates hearing loss. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, their efficacy in non-malignant tumors like VS remains largely unexamined.
Methods
We used immune-competent VS mouse models to assess the efficacy of combined anti-PD1 (αPD1) and RT treatment, tumor growth, and hearing preservation.
Results
We found three significant therapeutic benefits: i) RT induces immunogenic cell death and activates the STING pathway, enhancing αPD1 efficacy and generating long-term immune memory, ii) The combination strategy reduces the required RT dose necessary for effective tumor control, potentially minimizing RT injury to surrounding normal tissues, and iii) RT to peripheral nerve tumor induces a systemic abscopal effect, which enhances αPD-1 efficacy to effectively control intracranial schwannomas without direct irradiation, sparing the cochlea from radiation exposure and avoiding auditory radiation injury.
Conclusion
Our findings provide a compelling rationale for deploying ICIs in combination with radiotherapy as a novel treatment approach for patients with VS and NF2-SWN.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
- Department of Otolaryngology - Head and Neck Surgery and Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
- Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
- Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Funding
- NIDCD NIH HHS
- NINDS NIH HHS
Cite
APA
Yin, Z., Lu, S., Wu, L., Sun, Y., Blake, D. C., Chen, J., Landegger, L. D., Ho, W., Xiu, B., Jones, A. P., Muzikansky, A., Shih, H. A., Stankovic, K. M., Plotkin, S. R., & Xu, L. (2026). A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation. Theranostics. https://doi.org/10.7150/thno.123726
Vancouver
Yin Z, Lu S, Wu L, Sun Y, Blake DC, Chen J, et al. A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation. Theranostics. 2026. doi:10.7150/thno.123726
BibTeX
@article{Yin2026,
author = {Yin, Zhenzhen and Lu, Simeng and Wu, Limeng and Sun, Yao and Blake, Day Caven and Chen, Jie and Landegger, Lukas D and Ho, William and Xiu, Bingyu and Jones, Adam P and Muzikansky, Alona and Shih, Helen A and Stankovic, Konstantina M and Plotkin, Scott R and Xu, Lei},
title = {A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation},
journal = {Theranostics},
year = {2026},
doi = {10.7150/thno.123726}
}
EUVIMED